Trial Profile
A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Acronyms CENTAURUS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 12 Dec 2023 Final analysis presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Sep 2023 Planned End Date changed from 1 Jun 2024 to 3 Jun 2024.
- 16 Aug 2023 Planned End Date changed from 1 Aug 2023 to 1 Jun 2024.